de Pedro-Cuesta J, Petersen I J, Vassilopoulos D, Micheli F, Garcia-Inesta A
Department of Neurology, Huddinge Hospital, Sweden.
Acta Neurol Scand. 1991 May;83(5):328-35. doi: 10.1111/j.1600-0404.1991.tb04711.x.
This study is an analysis of the measurements of drug use by populations proposed by the Nordic Council on Medicines, conducted from an epidemiological-theoretical perspective. Particular attention is given to levodopa use (LDU). Several measurements of comparative LDU are proposed here for the assessment of levodopa (LD) consumption, from data on LD sales to well defined populations, over known periods of time. The method takes into account possible purposes of LDU evaluations, and is based on a reported model which combines information on Parkinson's Disease prevalence (PD) from surveys, gross levodopa sales, age-structure of the population, the figures for infant mortality rates (IMRs) taken as an indicator of modernization, and the average amount of LD prescribed as daily dose. The evaluation of LDU is implemented following a stepwise procedure.
本研究是从流行病学理论角度对北欧药品委员会提出的人群药物使用测量方法进行的分析。特别关注左旋多巴的使用（LDU）。本文提出了几种比较LDU的测量方法，用于根据已知时间段内左旋多巴（LD）向明确人群的销售数据评估其消费量。该方法考虑了LDU评估的可能目的，并基于一个报告模型，该模型结合了来自调查的帕金森病患病率（PD）信息、左旋多巴总销售额、人口年龄结构、作为现代化指标的婴儿死亡率（IMR）数据以及规定的每日剂量的LD平均量。LDU的评估按照逐步程序进行。
